International Journal of Hematology

DOI: 10.1007/s12185-019-02665-3 Pages: 512-516

Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions

1. The University of Tokyo, Department of Pediatrics

2. Kyoto University, Department of Pediatrics

Correspondence to:
Mitsuteru Hiwatari
Tel: 813-3815-5411



Patients with acute myeloid leukemia (AML) co-expressing NUP98/NSD1 and FLT3/ITD have a dismal prognosis despite undergoing hematopoietic stem cell transplantation (HSCT). There are a few studies on successful treatment of relapsed AML co-expressing NUP98/NSD1 and FLT3/ITD. We report a refractory case of molecular relapse of AML co-expressing NUP98/NSD1 and FLT3/ITD post-matched sibling HSCT. Donor lymphocyte infusion (DLI) at an early stage of post-transplantation resulted in complete molecular remission for 29 months with durable chronic graft-versus-host disease. Our case suggests the clinical efficacy of preemptive DLI following minimal residual disease analysis for the treatment of refractory AML.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge